A new bill introduced in Minnesota seeks to prohibit gene-based COVID-19 vaccines, adding to legislative momentum in 10 other states.

By yourNEWS Media Newsroom

Minnesota has become the eleventh state to introduce legislation targeting the use of mRNA-based vaccines, with HF 3152 proposing a ban on administering any vaccine developed using messenger RNA technology. The bill, filed on April 7, outlines fines of $500 per offense and potential disciplinary action for violators, signaling a broader state-level pushback against mRNA shot deployment.

The legislation defines banned substances as vaccines developed using “messenger ribonucleic acid technology, modified messenger ribonucleic acid technology, self-amplifying messenger ribonucleic acid technology, or deoxyribonucleic acid technology.” While no committee action has occurred to date, the measure is unlikely to advance in a state legislature with a Democrat-controlled Senate and an evenly divided House, and even less likely to be signed into law by Democrat Governor Tim Walz.

Nonetheless, the bill reflects a broader trend. According to McCullough Foundation epidemiologist Nicolas Hulscher, similar legislation has been filed in 10 other states, including Idaho, Iowa, and Montana in 2025 alone. Despite this momentum, Axios reports that none of the measures introduced thus far have become law.

Iowa state Sen. Doug Campbell, whose proposal initially sought an outright ban before being softened to a liability waiver requirement, emphasized the accountability issue. “If I was a manufacturer of car tires and they delammed at 1,000 miles, I should be liable for that,” Campbell said.

Concerns about mRNA vaccine safety persist among some lawmakers and researchers. The federal Vaccine Adverse Event Reporting System (VAERS) recorded 38,541 deaths, 220,494 hospitalizations, 22,247 heart attacks, and 28,908 myocarditis and pericarditis incidents as of March 28, with other associated adverse events. Researchers with the U.S. Centers for Disease Control and Prevention (CDC) have acknowledged “a high verification rate of reports of myocarditis to VAERS after mRNA-based COVID-19 vaccination,” suggesting “under-reporting is more likely” than the opposite.

A global analysis involving 99 million individuals across eight countries and published in Vaccine noted “significantly higher risks of myocarditis following the first, second and third doses” of mRNA-based COVID-19 vaccines. The study also flagged increased risks of “pericarditis, Guillain-Barré syndrome, and cerebral venous sinus thrombosis,” and concluded that “potential safety signals… require further investigation.”

In April 2024, the CDC was compelled by court order to release 780,000 additional reports of serious adverse effects tied to COVID-19 vaccines. Around the same time, a Japanese study found “statistically significant increases” in cancer deaths following third doses of the mRNA vaccines, positing several possible mechanisms linking the two.

Earlier this year, a Florida grand jury published its long-awaited findings, concluding that while serious harm affected only a small percentage of those vaccinated, there were “profound and serious issues” in the pharmaceutical industry’s vaccine review process. The panel cited reluctance by manufacturers to disclose adverse event data as one of the key failings.

Attention now turns to the national level, where President Donald Trump’s health team is under scrutiny for its future policy direction. Trump nominated Robert F. Kennedy Jr. to head the Department of Health and Human Services. Kennedy, a long-time critic of the vaccine establishment, was initially seen as a signal of change, though most of his statements since joining the Trump administration have shifted focus toward general vaccine reform and harmful food additives.

During confirmation hearings, Kennedy called Operation Warp Speed an “extraordinary accomplishment,” suggesting a nuanced stance that stops short of full condemnation.

President Trump himself has sent mixed signals on the vaccines, having both embraced the original rollout and nominated figures with opposing views on COVID-era health policies. While momentum grows in state legislatures to challenge mRNA vaccine use, the path forward at the federal level remains less clear.

SOURCE